CIK 0001557746
- Non-accelerated filer
- Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460571712
- Phone
- +1 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy 10% owner bought 244,200 shares at $14.00 ($3,418,800)
- 4 Open-market buy 10% owner bought 5,410 shares at $14.03 ($75,883)
- 4 Open-market buy 10% owner bought 34,999 shares at an average $14.89 ($521,095)
- 4 Open-market buy 10% owner bought 42,813 shares at $14.06 ($601,792)
- 4 Open-market buy 10% owner bought 335,455 shares at $11.00 ($3,690,005)
- 4 Open-market buy Director bought 454,545 shares at $11.00 ($4,999,995)
- 4 Open-market buy 10% owner bought 454,545 shares at $11.00 ($4,999,995)
- 4 Open-market buy Director bought 409,090 shares at $11.00 ($4,499,990)
- 4 Open-market buy 10% owner bought 409,090 shares at $11.00 ($4,499,990)
- 4 Conversion Chief Legal Officer acquired 3,738 shares (conversion)
- 4 Conversion Chief Financial Officer acquired 7,478 shares (conversion)
- 4 Conversion Director acquired 46,188 shares (conversion)
- 4 Open-market buy 10% owner bought 2,237,130 shares at an average $10.86 ($24,289,920)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 13,352 shares at $11.00 ($146,872)
- 4 Open-market buy Director bought 13,352 shares at $11.00 ($146,872)
Page 20 of 21 · 414 filings